Hundreds of people raise $84,000 for Pulmonary Fibrosis Foundation during annual walk in Pittsburgh
Hundreds of people gathered in Pittsburgh's Riverfront Park on Saturday for the Pulmonary Fibrosis Foundation's annual walk.
Participants walked on a one or two-mile course in support of those living with pulmonary fibrosis, a group of progressive lung diseases that cause scarring in the lungs, which limits oxygen intake necessary for major organs to function.
Pulmonary fibrosis currently affects more than 250,000 Americans, and 50,000 new cases are diagnosed each year, according to PFF.
Organizers say individuals and teams from the Pittsburgh region raised more than $84,000 to advance research for a cure for the life-threatening disease.
Download the FREE WPXI News app for breaking news alerts.
Follow Channel 11 News on Facebook and Twitter. | Watch WPXI NOW
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
38 minutes ago
- Yahoo
Instead of worrying about your weight, focus on avoiding fragility
Shift Your Mindset is an occasional series from CNN's Life, But Better team. We talk to experts about how to do things differently to live a better life. Anti-aging aspirations have turned longevity products and services into a wellness-industry gold mine. But who wants to add on years only to spend them struggling to move, dependent on others and unable to enjoy basic activities? What's the point of sticking around longer if you can't actually live life? Building and maintaining strength and mobility helps preserve the independence you need to age with dignity — and the actions you take now make all the difference. In their new book 'The Complete Bone and Joint Health Plan: Help Prevent and Treat Osteoporosis and Arthritis,' dietitian and personal trainer Sydney Nitzkorski and orthopedic surgeon and sports medicine specialist Dr. Jocelyn Wittstein share the strategic diet and exercise choices you can make now to help maintain your quality of life well into your later years. Nitzkorski is a sports dietitian at Marist University in Poughkeepsie, New York, and she runs a private fitness and nutrition practice. Wittstein is an associate professor at Duke University School of Medicine in Durham, North Carolina. This conversation has been edited and condensed for clarity. CNN: What's the biggest misconception about bone and joint health? Dr. Jocelyn Wittstein: Most people don't realize that bone mineral density (BMD) peaks at around age 30. After that, your goal is to maintain your BMD and try to slow down bone loss. For women, bone density decreases about 1% annually until menopause and then accelerates to 2% a year. Men experience a roughly 1% annual decline. The key is to build a strong foundation early and continue supporting your bone and joint health throughout your life. Another misconception is that cardiovascular exercise alone is enough to preserve mobility, but strength training and light impact exercises are critical, too. These activities can elevate the peak bone density of people in their teens and 20s, while people older than 30 need those same exercises to minimize loss. This is important considering that 1 in 4 adults will get osteoarthritis, and anyone older than age 50 has a heightened risk for both arthritis and osteoporosis, women in particular. A full 77% of postmenopausal women reported joint pain in a randomized study. Sydney Nitzkorski: As a dietitian, I find that people don't think enough about how much calcium they're taking in, and most people are not getting enough. Your body can't make the calcium it needs, not just for bones and teeth but also heart, muscle and nerve function. If you're not consuming enough, your body will raid the reserves in your skeleton to meet its requirements. This is why everybody, at every age, needs to get enough calcium. If you have kids, make sure they're consuming enough now, because this is when they're building bone mass. But sufficient calcium is still important even if you're 60 or beyond. Boosting your bone health is incredibly important at every age, and it's never too late to start taking proactive steps. CNN: Are calcium supplements necessary? Nitzkorski: Whole foods are the best sources for calcium, with supplementation as a secondary option. I recommend that people track their intake for a typical week and then adjust accordingly. Adults need 1,000 to 1,200 milligrams of calcium daily. Good sources include milk, fortified plant milks, broccoli and kale, as well as sardines and anchovies because you eat the bones. Wittstein: Plus bok choy, which I consider a superfood. It's the green vegetable with the highest bioavailability of calcium. The calcium your body gets from a food depends on two factors: the total calcium the food contains and the bioavailability of that calcium, or how well the body absorbs and uses the mineral. A cup of milk has 300 milligrams of calcium that is 30% bioavailable, while a cup of bok choy has 160 milligrams that is 55% bioavailable. Yet, each one provides the body with an equivalent amount of calcium: about 87.5 milligrams. Along with bok choy's excellent calcium bioavailability, it also provides fiber and vitamins A and C. I love to prepare this green vegetable superfood with garlic, ginger and olive oil, making it an excellent anti-inflammatory food for joints and overall health. CNN: Pressing question: Can we count the calcium from milk in coffee? Nitzkorski: Yes! In the book, Jocelyn and I share that we both nail our calcium targets by drinking a lot of milk with a little bit of coffee. It's true that consuming more than 300 milligrams per day of caffeine lowers your body's calcium absorption — but that's a high bar when you consider an 8-ounce cup of coffee contains around 100 milligrams and a double shot of espresso contains about 140 milligrams. Wittstein: Milk, whether it's from cows or a plant-based type that's been supplemented, is a good source of vitamin D, too. We know that consuming 2,000 IU of vitamin D a day can benefit bone health and . When it comes to coffee, people are often glad to learn that it is rich in anti-inflammatory antioxidants. It contains the polyphenol quercetin, which nd has anti-inflammatory properties. I like to add cinnamon to my coffee for added anti-inflammatory effect and glucose control. You can also add whey protein — which provides amino acids that your body uses to build muscle — and/or collagen supplements, which can improve both bone density and joint pain, depending on the type. CNN: What's the connection between inflammation and joint health? Wittstein: Inflammation can break down cartilage and contribute to joint pain. Chronic inflammation accelerates joint deterioration. Anti-inflammatory nutrition taken in through diet and supplements like omega-3 fatty acids and curcumin, for example, can help ease symptoms like pain and swelling. CNN: What does an anti-inflammatory diet look like? Nitzkorski: What I love about recommending anti-inflammatory foods is that they provide so many other benefits, too, such as decreasing heart attack risk, increasing longevity, improving digestion and giving you more energy. An anti-inflammatory diet is rich in lean proteins, which could be animal-based — such as non- or low-fat dairy, eggs, fish, chicken or turkey — or plant-based like beans, lentils and soy as well as pea proteins, which are found in a lot of protein powders. An anti-inflammatory diet also includes healthy fats, such as olive oil and foods containing omega-3 fatty acids like fish as well as walnuts and flax, chia and basil seeds. Alliums — including garlic, onion, leeks and shallots — are flavorful plants that have multiple anti-inflammatory properties. And there's a whole spectrum of spices including turmeric, cayenne, black pepper and ginger. Wittstein: Also important is dietary fiber from fruits, vegetables, beans and whole grains that provides short-chain fatty acids, higher levels of which are associated with lower levels of inflammation. Fruits and vegetables also contain myriad anti-inflammatory phytochemicals — naturally occurring compounds that provide an array of health benefits. Avoiding or limiting inflammatory ingredients like processed meats, red meat, fried foods, saturated fats and processed carbohydrates is also important. CNN: What types of exercise promote bone and joint health? Wittstein: It's critical to incorporate resistance training and impact exercises. The goal is to work into your 150 minutes of weekly activity a combination of the following: three days of weight-bearing aerobic exercise, two days of resistance training, and two days of balance work and light-impact exercises. That might sound like a lot, but these don't have to be long, intense sessions, and several of these types of conditioning can be combined. Standing on one leg and doing an overhead press counts as resistance training as well as balance work, for example. There are multiple things we want you to do to stimulate your bones and your muscles in different ways, but some of these activities can count as two. Nitzkorski: You can also integrate little exercises into your daily life. Just as we lose muscle and bone mass with age, we also lose our ability to balance. Practice intentionally throwing yourself off balance a little bit so your body must work to find its equilibrium again. Stand on one foot while brushing your teeth. Instead of sitting while watching TV, stand on one leg. Pretend a paintbrush is strapped to your toe and try to write your name or the alphabet. Write A through M on your right leg, and then switch and do N through Z on your left. To work on muscular endurance, do little arm circles. These start out super easy, but if you do them for two or three minutes it becomes exhausting. CNN: What do you mean by light-impact exercises? Wittstein: These include small jumps, jumping jacks or jumping rope. Studies show that doing 10 to 50 jumps three times a week is enough to stimulate your bone density. I encourage people to weave them into their day. By doing a little bit of hopping while you're waiting for the bus, you're getting your heart rate up and getting in some light-impact conditioning. CNN: Do you recommend jumping if it causes knee pain? Nitzkorski: No, people should listen to their joint pain! If jumping hurts your knees, focus on other kinds of conditioning like shallow squats, for example. You can also spread out your jumps over the course of the day or a week so you are not doing too many in a row. Or you can modify jumping exercises by using the back of a chair, or something else, for balance. Wittstein: Or try modifications like pool jumping, which adds resistance and partly reduces impact. Water-based exercises are not as effective as land-based jumping exercises, but they are definitely beneficial for bone mineral density. Although the gains from some of these exercise-based interventions may seem small, they actually translate to big risk reductions. We know from studies of pharmaceutical interventions that a 2% increase in lumbar-spine-bone density reduces spine fracture risk by 28%. A 4% improvement in hip-bone density decreases hip fracture risk by 32%. So even small improvements matter significantly. CNN: Is it ever too late to start boosting your bone and joint health? Nitzkorski: Absolutely not. While it's ideal to start early, you can always benefit from improving your diet and exercise routine. Start small — even 10 minutes of activity is better than nothing. Over time, small dietary changes can become a habit that sticks. The goal is consistency and gradual improvement so you can enjoy the life you live for that much longer. Editor's note: Sign up for CNN's Fitness, But Better newsletter series. Our seven-part guide will help you ease into a healthy routine, backed by experts. Jessica DuLong is a Brooklyn, New York-based journalist, book collaborator, writing coach and the author of 'Saved at the Seawall: Stories From the September 11 Boat Lift' and 'My River Chronicles: Rediscovering the Work That Built America.'
Yahoo
an hour ago
- Yahoo
Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with hemophilia A in new phase 3 data presented at the ISTH 2025 Congress
New FRONTIER5 results show a direct switch to investigational Mim8 (denecimig) prophylaxis treatment from emicizumab, without the need for a washout period, was well-tolerated in adults and adolescents with hemophilia A, with or without inhibitors1 FRONTIER5 Patient-Reported Outcomes assessment found the Mim8 pen-injector easy to use with strong user preference over their emicizumab injection system2 PLAINSBORO, N.J., June 22, 2025 /PRNewswire/ -- Novo Nordisk today presented results from the phase 3b FRONTIER5 trial showing that a direct switch to investigational Mim8 (denecimig) prophylaxis from emicizumab treatment, without a washout period or Mim8 loading dose, was well tolerated in adults and adolescents living with hemophilia A, with or without inhibitors.1 Additionally, a FRONTIER5 Patient-Reported Outcomes (PROs) assessment found the Mim8 pen-injector easy to use with an overall strong user preference for the pen-injector, in comparison to previous injection systems.2 The results were presented at the International Society on Thrombosis and Haemostasis (ISTH) Congress in Washington, D.C. "Continuous prophylactic coverage is critical to avoiding breakthrough bleeds in people living with hemophilia; with new non-factor therapeutic options, many people could have hesitations about switching treatment options. These data demonstrate that switching to Mim8 from emicizumab can be done without requiring a washout period," said Allison P. Wheeler, MD, Washington Center for Bleeding Disorders, Seattle, WA. "This is critical in ensuring that individuals maintain continuous protection against bleeding events as we seek to help address the ongoing needs of people living with this complex disease." In the open-label phase 3 FRONTIER5 safety study, 61 adults and adolescents aged 12 years and older with hemophilia A were enrolled.3 No thromboembolic events, hypersensitivity reactions, or treatment-emergent adverse events (TEAEs) leading to discontinuation were observed, and there was no evidence of neutralizing anti-Mim8 antibodies.1 Additional safety information from FRONTIER5 demonstrate that between Week 0 and Week 26 of treatment, there were 107 TEAEs observed in 43 patients (70.5%), most of which were mild to moderate (88.6%). There were 24 TEAEs that were possibly/probably related to Mim8 reported in 18 patients (29.5%). No thromboembolic events, hypersensitivity reactions, or TEAEs leading to discontinuation were observed.1 The PROs data from FRONTIER5 indicated overall (97%; n=57/59) patients preferred the Mim8 pen injection, with 97% of those patients reporting a "very strong" or "fairly strong" preference in comparison to their previous emicizumab injection system. Of the participants who completed the Hemophilia Device Handling and Preference Assessment (HDHPA) questionnaire at week 26, 98% (n=58/59) found the Mim8 pen-injector "very easy" or "easy" to use, and 95% (n=56/59) found it "much easier" or "easier" compared with their previous administration method. All participants (100%) were "extremely confident" or "very confident" in using the pen-injector correctly.2 "The FRONTIER5 safety and patient-reported outcomes data support Mim8 as a potential future treatment option for people living with hemophilia A and demonstrate our continued commitment to developing innovative treatment options for the hemophilia community," said Stephanie Seremetis, Chief Medical Officer and CVP for Rare Disease at Novo Nordisk. "These results give valuable insights into hemophilia A management, highlight the feasibility of directly switching to Mim8 from emicizumab, and reveal a strong patient preference for the Mim8 pen-injector device." Novo Nordisk aims to submit Mim8 for U.S. and EU regulatory review during 2025. Data from the ongoing phase 3 FRONTIER program will be disclosed at upcoming congresses and in publications in 2025 and 2026. About hemophiliaHemophilia is a rare inherited bleeding disorder that impairs the body's ability to make blood clots, a process needed to stop bleeding.4 It is estimated to affect approximately 1,125,000 people worldwide.5 There are different types of hemophilia, which are characterized by the type of clotting factor protein that is defective or missing.4 Hemophilia A is caused by a missing or defective clotting Factor VIII (FVIII), and hemophilia B is caused by a missing or defective clotting Factor IX.4 Inhibitors are an immune system response to the clotting factors in replacement therapy. Currently, it is estimated that up to 30% of people living with severe hemophilia A have inhibitors that can cause replacement therapies to stop working.6 About Mim8Mim8 is an investigational FVIIIa mimetic bispecific antibody designed with the aim to deliver once-monthly, once-every-two-weeks, or once-weekly prophylaxis for people living with hemophilia A, with or without inhibitors.7,8 Administered under the skin, Mim8 bridges Factor IXa and Factor X. This action replaces FVIII function, which helps restore the body's thrombin generation capacity, helping blood to clot.7,9 The use of Mim8 in people living with hemophilia A is investigational and not approved by regulatory authorities or available anywhere in the world. About the FRONTIER5 trialFRONTIER5 is a single-arm, open-label, 26-week, phase 3b trial evaluating the safety of switching from previous emicizumab prophylaxis treatment directly to Mim8 prophylaxis treatment using the Mim8 pen-injector in adults and adolescents with hemophilia A, with or without inhibitors.1 The FRONTIER clinical program investigates Mim8 as a prophylaxis treatment for people with hemophilia A, with or without inhibitors. The phase 3 program includes FRONTIER1, FRONTIER2, FRONTIER3, FRONTIER4 and FRONTIER5.1,8,10-12 About Novo Nordisk Novo Nordisk is a leading global healthcare company that's been making innovative medicines to help people with diabetes lead longer, healthier lives for more than 100 years. This heritage has given us experience and capabilities that also enable us to drive change to help people defeat other serious chronic diseases such as obesity, rare blood, and endocrine disorders. We remain steadfast in our conviction that the formula for lasting success is to stay focused, think long-term, and do business in a financially, socially, and environmentally responsible way. With a U.S. presence spanning 40 years, Novo Nordisk U.S. is headquartered in New Jersey and employs over 10,000 people throughout the country across 12 manufacturing, R&D, and corporate locations in eight states plus Washington DC. For more information, visit Facebook, Instagram, and X. Contacts for further information: Media: Liz Skrbkova (US)+1 609 917 0632NNIMediaTeam@ James-Brown (Global)+45 3079 9289Globalmedia@ Investors: Frederik Taylor Pitter (US) +1 609 613 0568fptr@ Martin Wiborg Rode (Global)+45 3075 5956jrde@ Meyer (Global) +45 3079 6656 azey@ Schaap Melvold (Global) +45 3077 5649 idmg@ Ung (Global)+45 3077 6414mxun@ References Oldenberg J, Benson G, Chowdaryet P, et al. FRONTIER5 direct switch study: safety of initiating Mim8 prophylaxis without washout of emicizumab. Oral presentation presented at the Congress of the International Society on Thrombosis and Haemostasis 2025; June 21-25 2025; Walter E. Washington Convention Center, Washington D.C., US. Session code 13686. Mahlangu J, Ahuja S, Cockrell E, et al. FRONTIER5 device handling and patient-reported outcomes. Oral presentation presented at the Congress of the International Society on Thrombosis and Haemostasis 2025; June 21–25 2025; Walter E. Washington Convention Center, Washington D.C., US. Session code 13786. A Research Study Looking at How Safe it is to Switch From Emicizumab to Mim8 in People With Haemophilia A (FRONTIER5). Last accessed May 2025. Available at MedlinePlus. Hemophilia. Last accessed May 2025. Available at Iorio A, Stonebraker JS, Chambost H, et al. Establishing the Prevalence and Prevalence at Birth of Hemophilia in Males: A Meta-analytic Approach Using National Registries. Ann Intern Med. 2019;171:540-546. Kim JY, You CW. The prevalence and risk factors of inhibitor development of FVIII in previously treated patients with hemophilia A. Blood Res. 2019;54:204-209. Ostergaard H, Lund J, Greisen PJ, et al. A factor VIIIa-mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice. Blood. 2021;138:1258-1268. A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A (FRONTIER4). Last accessed May 2025. Available at U.S. National Library of Medicine. F8 gene. MedlinePlus Genetics. Last accessed May 2025. Available at A Research Study Investigating Mim8 in People With Haemophilia A. Last accessed June 2025. Available at A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors. Last accessed May 2025. Available at A Research Study Looking at Mim8 in Children With Haemophilia A With or Without Inhibitors. Last accessed May 2025. Available at Novo Nordisk is a registered trademark of Novo Nordisk A/S. © 2025 Novo Nordisk All rights reserved. US25HRBD00174 June 2025 View original content to download multimedia: SOURCE Novo Nordisk Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with hemophilia A in new phase 3 data presented at the ISTH 2025 Congress
New FRONTIER5 results show a direct switch to investigational Mim8 (denecimig) prophylaxis treatment from emicizumab, without the need for a washout period, was well-tolerated in adults and adolescents with hemophilia A, with or without inhibitors1 FRONTIER5 Patient-Reported Outcomes assessment found the Mim8 pen-injector easy to use with strong user preference over their emicizumab injection system2 PLAINSBORO, N.J., June 22, 2025 /PRNewswire/ -- Novo Nordisk today presented results from the phase 3b FRONTIER5 trial showing that a direct switch to investigational Mim8 (denecimig) prophylaxis from emicizumab treatment, without a washout period or Mim8 loading dose, was well tolerated in adults and adolescents living with hemophilia A, with or without inhibitors.1 Additionally, a FRONTIER5 Patient-Reported Outcomes (PROs) assessment found the Mim8 pen-injector easy to use with an overall strong user preference for the pen-injector, in comparison to previous injection systems.2 The results were presented at the International Society on Thrombosis and Haemostasis (ISTH) Congress in Washington, D.C. "Continuous prophylactic coverage is critical to avoiding breakthrough bleeds in people living with hemophilia; with new non-factor therapeutic options, many people could have hesitations about switching treatment options. These data demonstrate that switching to Mim8 from emicizumab can be done without requiring a washout period," said Allison P. Wheeler, MD, Washington Center for Bleeding Disorders, Seattle, WA. "This is critical in ensuring that individuals maintain continuous protection against bleeding events as we seek to help address the ongoing needs of people living with this complex disease." In the open-label phase 3 FRONTIER5 safety study, 61 adults and adolescents aged 12 years and older with hemophilia A were enrolled.3 No thromboembolic events, hypersensitivity reactions, or treatment-emergent adverse events (TEAEs) leading to discontinuation were observed, and there was no evidence of neutralizing anti-Mim8 antibodies.1 Additional safety information from FRONTIER5 demonstrate that between Week 0 and Week 26 of treatment, there were 107 TEAEs observed in 43 patients (70.5%), most of which were mild to moderate (88.6%). There were 24 TEAEs that were possibly/probably related to Mim8 reported in 18 patients (29.5%). No thromboembolic events, hypersensitivity reactions, or TEAEs leading to discontinuation were observed.1 The PROs data from FRONTIER5 indicated overall (97%; n=57/59) patients preferred the Mim8 pen injection, with 97% of those patients reporting a "very strong" or "fairly strong" preference in comparison to their previous emicizumab injection system. Of the participants who completed the Hemophilia Device Handling and Preference Assessment (HDHPA) questionnaire at week 26, 98% (n=58/59) found the Mim8 pen-injector "very easy" or "easy" to use, and 95% (n=56/59) found it "much easier" or "easier" compared with their previous administration method. All participants (100%) were "extremely confident" or "very confident" in using the pen-injector correctly.2 "The FRONTIER5 safety and patient-reported outcomes data support Mim8 as a potential future treatment option for people living with hemophilia A and demonstrate our continued commitment to developing innovative treatment options for the hemophilia community," said Stephanie Seremetis, Chief Medical Officer and CVP for Rare Disease at Novo Nordisk. "These results give valuable insights into hemophilia A management, highlight the feasibility of directly switching to Mim8 from emicizumab, and reveal a strong patient preference for the Mim8 pen-injector device." Novo Nordisk aims to submit Mim8 for U.S. and EU regulatory review during 2025. Data from the ongoing phase 3 FRONTIER program will be disclosed at upcoming congresses and in publications in 2025 and 2026. About hemophiliaHemophilia is a rare inherited bleeding disorder that impairs the body's ability to make blood clots, a process needed to stop bleeding.4 It is estimated to affect approximately 1,125,000 people worldwide.5 There are different types of hemophilia, which are characterized by the type of clotting factor protein that is defective or missing.4 Hemophilia A is caused by a missing or defective clotting Factor VIII (FVIII), and hemophilia B is caused by a missing or defective clotting Factor IX.4 Inhibitors are an immune system response to the clotting factors in replacement therapy. Currently, it is estimated that up to 30% of people living with severe hemophilia A have inhibitors that can cause replacement therapies to stop working.6 About Mim8Mim8 is an investigational FVIIIa mimetic bispecific antibody designed with the aim to deliver once-monthly, once-every-two-weeks, or once-weekly prophylaxis for people living with hemophilia A, with or without inhibitors.7,8 Administered under the skin, Mim8 bridges Factor IXa and Factor X. This action replaces FVIII function, which helps restore the body's thrombin generation capacity, helping blood to clot.7,9 The use of Mim8 in people living with hemophilia A is investigational and not approved by regulatory authorities or available anywhere in the world. About the FRONTIER5 trialFRONTIER5 is a single-arm, open-label, 26-week, phase 3b trial evaluating the safety of switching from previous emicizumab prophylaxis treatment directly to Mim8 prophylaxis treatment using the Mim8 pen-injector in adults and adolescents with hemophilia A, with or without inhibitors.1 The FRONTIER clinical program investigates Mim8 as a prophylaxis treatment for people with hemophilia A, with or without inhibitors. The phase 3 program includes FRONTIER1, FRONTIER2, FRONTIER3, FRONTIER4 and FRONTIER5.1,8,10-12 About Novo Nordisk Novo Nordisk is a leading global healthcare company that's been making innovative medicines to help people with diabetes lead longer, healthier lives for more than 100 years. This heritage has given us experience and capabilities that also enable us to drive change to help people defeat other serious chronic diseases such as obesity, rare blood, and endocrine disorders. We remain steadfast in our conviction that the formula for lasting success is to stay focused, think long-term, and do business in a financially, socially, and environmentally responsible way. With a U.S. presence spanning 40 years, Novo Nordisk U.S. is headquartered in New Jersey and employs over 10,000 people throughout the country across 12 manufacturing, R&D, and corporate locations in eight states plus Washington DC. For more information, visit Facebook, Instagram, and X. Contacts for further information: Media: Liz Skrbkova (US)+1 609 917 0632NNIMediaTeam@ James-Brown (Global)+45 3079 9289Globalmedia@ Investors: Frederik Taylor Pitter (US) +1 609 613 0568fptr@ Martin Wiborg Rode (Global)+45 3075 5956jrde@ Meyer (Global) +45 3079 6656 azey@ Schaap Melvold (Global) +45 3077 5649 idmg@ Ung (Global)+45 3077 6414mxun@ References Oldenberg J, Benson G, Chowdaryet P, et al. FRONTIER5 direct switch study: safety of initiating Mim8 prophylaxis without washout of emicizumab. Oral presentation presented at the Congress of the International Society on Thrombosis and Haemostasis 2025; June 21-25 2025; Walter E. Washington Convention Center, Washington D.C., US. Session code 13686. Mahlangu J, Ahuja S, Cockrell E, et al. FRONTIER5 device handling and patient-reported outcomes. Oral presentation presented at the Congress of the International Society on Thrombosis and Haemostasis 2025; June 21–25 2025; Walter E. Washington Convention Center, Washington D.C., US. Session code 13786. A Research Study Looking at How Safe it is to Switch From Emicizumab to Mim8 in People With Haemophilia A (FRONTIER5). Last accessed May 2025. Available at MedlinePlus. Hemophilia. Last accessed May 2025. Available at Iorio A, Stonebraker JS, Chambost H, et al. Establishing the Prevalence and Prevalence at Birth of Hemophilia in Males: A Meta-analytic Approach Using National Registries. Ann Intern Med. 2019;171:540-546. Kim JY, You CW. The prevalence and risk factors of inhibitor development of FVIII in previously treated patients with hemophilia A. Blood Res. 2019;54:204-209. Ostergaard H, Lund J, Greisen PJ, et al. A factor VIIIa-mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice. Blood. 2021;138:1258-1268. A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A (FRONTIER4). Last accessed May 2025. Available at U.S. National Library of Medicine. F8 gene. MedlinePlus Genetics. Last accessed May 2025. Available at A Research Study Investigating Mim8 in People With Haemophilia A. Last accessed June 2025. Available at A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors. Last accessed May 2025. Available at A Research Study Looking at Mim8 in Children With Haemophilia A With or Without Inhibitors. Last accessed May 2025. Available at Novo Nordisk is a registered trademark of Novo Nordisk A/S. © 2025 Novo Nordisk All rights reserved. US25HRBD00174 June 2025 View original content to download multimedia: SOURCE Novo Nordisk Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
